{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["19(1)"],"submitter":["Ozcan G"],"pubmed_abstract":["<h4>Objective</h4>Taxane-based neoadjuvant chemotherapy is the most common neoadjuvant approach in breast cancer, especially in human epidermal growth factor receptor 2 (HER2)-positive and triple-negative subtypes. However, chemoresistance is a problem in many patients, and success rates are low in estrogen receptor (ER)-positive breast cancer. The aim of this study was to identify predictive markers for resistance to taxane-based therapy, which may have a potential as therapeutic targets in breast cancer.<h4>Materials and methods</h4>Three comprehensive breast cancer Gene Expression Omnibus datasets were analyzed to identify differentially expressed genes (DEGs) in breast cancer patients resistant to taxane-based neoadjuvant chemotherapy. Functional annotation clustering and enrichment an"],"journal":["European journal of breast health"],"pagination":["45-54"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9806940"],"repository":["biostudies-literature"],"pubmed_title":["<i>SCUBE2</i> as a Marker of Resistance to Taxane-based Neoadjuvant Chemotherapy and a Potential Therapeutic Target in Breast Cancer."],"pmcid":["PMC9806940"],"pubmed_authors":["Ozcan G"],"additional_accession":[]},"is_claimable":false,"name":"<i>SCUBE2</i> as a Marker of Resistance to Taxane-based Neoadjuvant Chemotherapy and a Potential Therapeutic Target in Breast Cancer.","description":"<h4>Objective</h4>Taxane-based neoadjuvant chemotherapy is the most common neoadjuvant approach in breast cancer, especially in human epidermal growth factor receptor 2 (HER2)-positive and triple-negative subtypes. However, chemoresistance is a problem in many patients, and success rates are low in estrogen receptor (ER)-positive breast cancer. The aim of this study was to identify predictive markers for resistance to taxane-based therapy, which may have a potential as therapeutic targets in breast cancer.<h4>Materials and methods</h4>Three comprehensive breast cancer Gene Expression Omnibus datasets were analyzed to identify differentially expressed genes (DEGs) in breast cancer patients resistant to taxane-based neoadjuvant chemotherapy. Functional annotation clustering and enrichment an","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2025-04-04T08:33:47.933Z","creation":"2025-04-04T08:33:47.933Z"},"accession":"S-EPMC9806940","cross_references":{"pubmed":["36605472"],"doi":["10.4274/ejbh.galenos.2022.2022-8-2"]}}